a.k.a. Brands GAAP EPS of -$0.70 misses by $0.04, revenue of $161.3M misses by $0.21M (AKA:NYSE)

a.k.a. Brands reported Q3 GAAP EPS of -$0.70, missing estimates by $0.04. Revenue was $161.3M, up 9.7% Y/Y but missing by $0.21M. Net sales growth was driven by a 12.8% increase in orders, with a 7.6% increase on a constant currency basis.

Original reporting
Published Nov 5, 2026, 2:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AKA
Bearish
medium confidence
Mentioned
$AKA
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AKABearishMed
01

Why it matters

The earnings miss may prompt short-term price declines, but the modest size of the miss could limit the move.

02

Market read

Earnings release for a micro‑cap; relevance primarily to traders focused on small‑cap earnings volatility.

03

What to watch

Potential cost reductions or upcoming product launches not disclosed in the release could mitigate the miss.

Relevance 7/10Novelty 7/10Timing: today

Background

a.k.a. Brands (NYSE:AKA) reported its Q3 2026 earnings, showing a slight miss on both EPS and revenue.

Company-level read

Ticker impact

$AKABearishMedium confidence
Context

Q3 GAAP EPS of -$0.70 missed expectations by $0.04 and revenue of $161.3M missed by $0.21M.

Expected impact

likely downward pressure as the market prices in the earnings miss

Evidence & confidence

Both EPS and revenue fell short of consensus, which typically leads to a negative reaction for a small-cap.

Market effects

Minor impact on the consumer packaged goods sector; peers may see slight comparative pressure.

Limited to U.S. small-cap investors.

Low; no broader macro implications.

Counterpoint

If the miss is within a narrow range, the stock could be oversold and present a buying opportunity.

Key entities

  • a.k.a. Brands

    U.S.-listed consumer goods company (ticker AKA).

Related articles

$AKAMed

A.K.A. BRANDS HOLDING CORP. (AKA): Net Sales Increased 9.7% to $161.3 Million, with U.S. Net Sales Up 14% Gross Margin Expansion and Continued Progress Across Strategic Priorities

A.K.A. BRANDS HOLDING CORP. (AKA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 a.k.a. Brands Holding Corp. Reports Third Quarter 2026 Financial Results Net Sales Increased 9.7% to $161.3 Million, with U.S. Net Sales Up 14% Gross Margin Expansion and Continued Progress Across Strategic Priorities SAN FRANCISCO – November 4, 2026 – a.k.a. Brands

$AKAMedAI 8/10

a.k.a. Brands Q2 Earnings Call Highlights

a.k.a. Brands (NYSE:AKA) reported Q2 orders down 0.5% to 2.04M and active customers up 4.4% to 4.31M, with average order value at $78. Gross margin rose 360 bps to 61.1% on lower tariffs and streetwear mix. Management guided Q3 gross margin near 59% and fiscal 2026 net sales $625M-$635M, adjusted EBITDA $30M-$32M.

$AKAMed

A.K.A. BRANDS HOLDING CORP. (AKA): Results of Operations and Financial Condition

A.K.A. BRANDS HOLDING CORP. (AKA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 a.k.a. Brands Holding Corp. Reports Second Quarter 2026 Financial Results Reiterates Full Year 2026 Outlook Princess Polly Targets a Minimum of 100 U.S. Stores Long Term Culture Kings Signs Puerto Rico Store Lease, Nears Agreement on New Store in Major U.S. Market SA

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.